Skip to content

Released May 7, 2026, after the close

10-Q filed May 7, 2026, 37 days after period end · 0001104659-26-057198

Q1 2026 · 10-Q
Revenue$5.34M+128.0% vs Q1 2025−20.5% vs Q4 2025
Net Income-$7.05MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted$0.19−47.2% vs Q1 2025no prior Q4 2025 on file
Gross Profit$3,832,000+106.8%
Operating Income-$8,021,000N/M
Operating Cash Flow-$8,583,000N/M
Margins · derived
Gross margin71.8%−7.4 pt vs Q1 2025
Operating margin-150.3%+326.7 pt vs Q1 2025
Net margin-132.2%+325.9 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024
Revenue$5.34M$2.34M$1.22M
Net Income-$7.05M-$10.72M-$6.59M
EPS Diluted$0.19$0.36$0.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR